VIR Q4 2025 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M+417.8% YoY

Gross Profit

$431M672.1% margin

Operating Income

-$37M-57.1% margin

Net Income

-$43M-67.0% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+26595.8%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$21M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$238M

Stockholders' Equity

$765M

Cash & Equivalents

$234M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$12M	+417.8%
Gross Profit	$431M	-$76M	+663.5%
Operating Income	-$37M	-$117M	+68.7%
Net Income	-$43M	-$105M	+59.0%

Revenue Segments

Grant

$310,000100%

Geographic Segments

Non-US

$61M99%

UNITED STATES

$310,0001%